[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Gastritis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 58 pages | ID: GFF469DC6A87EN
VPAResearch

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Gastritis PIPELINE HIGHLIGHTS
Gastritis is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline’s potential. Development of Gastritis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Gastritis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Gastritis.

Good progress is anticipated during 2020 and 2021 with Gastritis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Gastritis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Gastritis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Gastritis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Gastritis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Gastritis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Gastritis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Gastritis DRUG PROFILES
Gastritis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Gastritis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Gastritis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Gastritis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 8 Gastritis companies including company overview, key snapshot, contact information, and their strategies on accelerating Gastritis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Addpharma Inc, Allakos Inc, CalyGene Biotechnology Inc, Kyowa Kirin Co Ltd, Otsuka Holdings Co Ltd, Recce Pharmaceuticals Ltd, RedHill Biopharma Ltd, Trio Medicines Ltd

REASONS TO BUY
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Gastritis
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO GASTRITIS

1.1 Gastritis- Disease overview
1.2 Gastritis- Market Size
1.3 Gastritis- Companies Involved

2. GASTRITIS PIPELINE SNAPSHOT- 2020

2.1 Gastritis Pipeline by Phase
2.2 Gastritis Pipeline by Mechanism of Action
2.3 Gastritis Pipeline by Route of Administration
2.4 Gastritis Pipeline- New Molecular Entities
2.5 Gastritis Pipeline- Orphan Drug Designation/ Special Designation

3. GASTRITIS DRUG PROFILES

3.1 Current Status
3.2 Gastritis Drug Snapshot
3.3 Gastritis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Addpharma Inc Gastritis Pipeline Insights and Clinical Trials
4.2 Allakos Inc Gastritis Pipeline Insights and Clinical Trials
4.3 CalyGene Biotechnology Inc Gastritis Pipeline Insights and Clinical Trials
4.4 Kyowa Kirin Co Ltd Gastritis Pipeline Insights and Clinical Trials
4.5 Otsuka Holdings Co Ltd Gastritis Pipeline Insights and Clinical Trials
4.6 Recce Pharmaceuticals Ltd Gastritis Pipeline Insights and Clinical Trials
4.7 RedHill Biopharma Ltd Gastritis Pipeline Insights and Clinical Trials
4.8 Trio Medicines Ltd Gastritis Pipeline Insights and Clinical Trials

5. GASTRITIS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information


More Publications